




# Future directions and current challenges of proton radiotherapy.




Tony Lomax

Centre for Proton Radiotherapy, Paul Scherrer Institute, Switzerland



# Overview of presentation

- New developments in treatment delivery
  - Current challenges
  - Potential solutions
  - Summary



# Industrial suppliers of radiotherapy equipment

Manufacturers currently offering photon therapy equipment

Varian

Elekta

Tomotherapy

Siemens

Manufacturers currently offering particle therapy equipment

IBA\*

Hitachi\*

Optivus\*


Varian/Accell\*\*

Siemens\*\*



Still River systems

\* Scanning option available

\*\* Scanning only




# Laser based acceleration




# Laser based acceleration

## Energy spectrum




- Maximum proton energy reported so far is  $E_p \approx 60$  MeV
- High intensity ( $10^9$ - $10^{11}$  protons) in very short pulse ( $\sim$ ns)
- Very poor (broad) energy spectrum

R. A. Snavely, *et al.*, *Phys. Rev. Lett.* Vol. 85, 2945, (2000)



# Laser based acceleration

## Achieving mono-energetic spectrums




$I = 3 \times 10^{19} \text{ W/cm}^2$

5  $\mu\text{m}$  thick Ti foil

0.5  $\mu\text{m}$  thick PMMA  
dot (20x20  $\mu\text{m}$ )

1.2 MeV 'mono'-  
energetic protons  
produced


Schwoerer et al, Nature [439](#), 445 (2006)




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax

# Dielectric Wall Accelerators



Thanks to Rock Mackie, UWisc/Tomotherapy Inc




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax

# Dielectric Wall Accelerators


- DWA is a multi-stage inductive accelerator under development at Lawrence Livermore National Lab.
- Acceleration gradient of 100 MV/m possible.
- 200 MeV protons in 2 meters.
- This has been demonstrated in 'small' examples, with lengths of 2mm!
- Beam energy, intensity and spot size variable pulse-to-pulse.






# Dielectric Wall Accelerators

## Proton tomotherapy




G Caporaso, S Hawkins LLNL

- Incorporation of DWA into a CT like treatment gantry for rotational delivery of proton therapy
- Single room facility
- Diameter ~ 5m
- Under investigation by Tomotherapy Inc. and LLNL




# Proton Multi-leaf collimators



Particle MLC from Chiba (Japan)

- Saves changing collimators every field
- Can be used to 'simulate' scanning



# Proton Multi-leaf collimators

Film dosimetry performed at Loma Linda using  
MLC and passively scattered proton beam


Shape at surface



Shape after 29cm water






Mike Moyers, Loma Linda




# Proton Multi-leaf collimators

Simulated scanning using dynamic MLC's




# Overview of presentation

- New developments in treatment delivery
- Current challenges
- Potential solutions
- Summary



# Current challenges

- The neutron problem
  - Range uncertainty
- Dealing with organ motion



# Neutron dose during proton therapy: Is there a problem?

Hall, E. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *Int J Radiat Oncol Biol Phys* 2006 ; 65 : 1–7

Neutron equivalent dose  
a factor 10 higher for  
passive protons than for  
IMRT?






Fig. 10. The equivalent dose outside the edge of the treatment field as a fraction of the dose at the isocenter for protons with passive modulation, for a scanning proton beam, and for 6-MV X-rays, either 4-field conformal radiation therapy (CRT), or intensity-modulated radiation therapy (IMRT). The doses are rough estimates and are likely to be highly facility dependent. The passive-modulation: proton data are from Yan *et al.* (19), renormalized to a 10-cm  $\times$  10-cm field and to a neutron relative biologic effectiveness (RBE) or quality factor of 10. The pencil-beam scanning proton data are from Schneider *et al.* (18), renormalized to a 10-cm  $\times$  10-cm field and an RBE or quality factor of 10. Both proton curves were produced by Dr. Harald Paganetti, Massachusetts General Hospital and Harvard Medical School. X-ray data are 4-field CRT and IMRT. Unpublished data for a 6-MV linear accelerator were provided by Dr. C. W. Wu, Columbia University Medical Center, New York.




## Neutron dose during proton therapy: Is there a problem?

- Neutron dose equivalent from spot scanning and 15MV photons:
- Irradiation of 10 cm x 10 cm (x10cm) target to 50Gy

[Schneider U, Fiechtner A, Besserer J, Lomax A.J. Neutron dose from prosthesese materials during radiotherapy with protons and photons. Phys Med Biol 2004; 49:N119-124]




- Higher neutron dose in direction of beam
- Comparable neutron dose laterally
- Neutron dose very small compared to primary dose (~1000x smaller)





# Neutron dose during proton therapy: Is there a problem?




Passive Modulation\_1: Yan et al.



Passive Modulation\_2: Mesoloras et al.

IMRT: Stovall et al. (3DCRT up-scaled by a factor of 3)


Scanning: Schneider et al.



## Neutron dose during proton therapy: Is there a problem?




Don't forget primary dose – in this case  
reduced by a factor 6 for proton vs photons!



# Current challenges




- The neutron problem
- Range uncertainty
- Dealing with organ motion



# Range uncertainty


The advantage of protons is that they stop.

The disadvantage of protons is that we don't always know where...




# Sources of range uncertainties


- Limitations of CT data (beam hardening, noise, resolution etc) [ $\Sigma \sim 1\%$ ]
- Calibration of CT to stopping power [ $\Sigma \sim 1\text{-}2\%$ ]
- CT artifacts [ $\Sigma$ ]
- Variations in proton beam energy [ $\sigma (\sim 0.1\%)$ ]
- Variations in patient positioning [ $\sigma (\sim 1\text{-}3\text{mm})$ ]
- Variations in patient anatomy [ $\Sigma, \sigma$ ]




# The problem of CT artifacts



Rutz et al (PSI), To be submitted to IJROBP




# The problem of CT artifacts



- More advanced initial tumour at diagnosis?
- Problems in defining CTV?
- Problems in dose calculation?
- Problems in range calculations?


Rutz et al (PSI), To be submitted to IJROBP



## Variations in patient anatomy


### Patient set-up inaccuracies

Jan 08



Chen, Rosenthal, et al., IJROBP 48(3):339, 2000

Image courtesy of Thomas Bortfeld, MGH, Boston






## Variations in patient anatomy


### Patient set-up inaccuracies

Jan 11




Chen, Rosenthal, et al., IJROBP 48(3):339, 2000

Image courtesy of Thomas Bortfeld, MGH, Boston



## Variations in patient anatomy


3 field IMPT plan to an 8 year old boy



Note, sparing of spinal cord in middle of PTV

Francesca Albertini and Alessandra Bolsi (PSI)


During treatment, 1.5kg weight gain was observed




Max range differences:

SC 0.8cm


CTV 1.5cm



# Variations in patient anatomy




## Dose differences



## Differences between nominal and 'weight gain' CT's

Francesca Albertini and Alessandra Bolsi (PSI)




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax


# Current challenges

- The neutron problem
- Range uncertainty
- Dealing with organ motion




# Organ motion and range uncertainty

exhale




inhale




Engelsman et al., IJROBP 64(5):1589-1595, 2006

Images courtesy of Thomas Bortfeld, MGH, Boston




# Organ motion and the 'interplay' effect

A scanned  
beam in a  
static  
patient...



4D-CT derived from 4D-MRI

Martin von Siebenthal, Phillipe Cattin, Gabor Szekeley, Tony Lomax, ETH, Zurich and PSI, Villigen




Nuclear data for science and  
technology: Medical applications


Future directions and current  
challenges for proton therapy.  
Tony Lomax

# Organ motion and the 'interplay' effect

...but real  
patients move.




Martin von Siebenthal, Phillipe Cattin, Gabor Szekely, Tony Lomax, ETH, Zurich and PSI, Villigen



Nuclear data for science and  
technology: Medical applications


Future directions and current  
challenges for proton therapy.  
Tony Lomax

# Organ motion and the 'interplay' effect



Assume  $\sigma = 0.5\text{cm}$   
For this example, dose errors of ~20% can result from motion (positioning) errors of 2.5mm

Phillips et al., PMB, 37:223-234,1992








# Organ motion and the 'interplay' effect

Nominal (static) dose


Calculated with 'real'  
motion from 4D-MRI of  
volunteer



# Organ motion and the 'interplay' effect



Motion patient 1

Amplitude ~ 11mm




Motion patient 2

Amplitude ~ 8mm




# Overview of presentation

- New developments in treatment delivery
- Current challenges
- Potential solutions
- Summary




# Potential solutions to ...


- ...range uncertainty
- ...the organ motion problem



# Mega-Voltage CT for artifact free imaging




Accuracy of range calculation  
due to reconstruction artifacts?



No artifacts and linear relationship  
CT units to proton stopping power



Francesca Albertini (PSI)




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax

# Mega-Voltage CT for artifact free imaging




## Stopping power profiles



kV-CT  
artifacts



Prosthesis

Francesca Albertini (PSI)





# Range adapted proton therapy

Automatic adaptation of Bragg peak ranges on a spot by spot basis depending on local change in range



# Range adapted proton therapy



Automatic adaptation of Bragg peak ranges on a spot by spot basis depending on local change in range






# Range adapted proton therapy


Automatic adaptation of Bragg peak ranges on a spot by spot basis depending on local change in range





# Range adapted proton therapy



not adapted-nominal






adapted -nominal




# Robust planning techniques


## Example paraspinal case



Lomax et al.: Med. Phys. 28(3): 317-324, 2001






# Robust planning techniques




3 patched,  
intensity  
modulated  
fields....

Lomax et al.: Med. Phys.  
28(3): 317-324, 2001




...give a homogenous  
dose without the use  
of fields that abut  
distally against the  
spinal cord




# Robust planning techniques

Nominal plans 10% overshoot plans


IMPT




IMPT



Single field




Single field




DVH analysis

Spinal cord



Single field — Nominal  
 ..... Overshoot  
 IMPT plan — Nominal  
 ..... Overshoot



# Robust planning techniques

Incorporate range uncertainty into optimisation function using gaussian probability functions for range uncertainty

E.g.


$$\underset{\mathbf{w}}{\text{minimize}} \quad \langle E(\mathbf{w}) \rangle := \int \sum_{i \in PAT} \alpha_i [D_i(\mathbf{w}, \bar{\rho} + \sigma \delta) - D_i^{pres}]^2 P(\delta) d\delta$$

subject to






$$w_j \geq 0 \quad (\forall j \in PB)$$

Where  $\bar{\rho} + \sigma \delta$  assigns an uncertainty to the range of each pencil beam in the optimisation

Unkelbach et al, PMB, 52;2755-2773, 2007




# Robust planning techniques



Optimised fields  
using 'robust'  
optimisation

Unkelbach et al, PMB,  
52;2755-2773, 2007




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax




# Robust planning techniques


Effect of 5mm range uncertainty on robustly optimised plan



nominal range




5 mm undershoot



5 mm overshoot


Unkelbach et al, PMB, 52;2755-2773, 2007





# Potential solutions to ...



- ...range uncertainty
- ...the organ motion problem



# Tumour tracking




Track motion of tumour  
using scanning system  
based on some  
anatomical/physiological  
signal

- + Most conformal
- + Most efficient
- Very complex!
- Difficult QA
- Reliability of tracking signal?




# Tumour tracking

## Dose heterogeneity as function of tracking delay





Steven van de Water, PSI



# Rescanning


Repaint scanned beam many times such that statistics dictate coverage and homogeneity of dose in target (c.f. fractionation)

- + Simple method
- + Robust
- Fast scanning required
- Not very conformal




# Rescanning


Nominal dose – no motion



Dose with +/- 1 cm motion




Dose with +/- 1 cm motion and 11x rescanning



Applying the total prescribed dose in  $n$  steps (each spot is applied  $n$  times rather than once) provides a better homogeneity.

The error is statistically decreased by  $\sqrt{n}$

Christian Hilbes, PSI




Nuclear data for science and technology: Medical applications

Future directions and current challenges for proton therapy.  
Tony Lomax

# Rescanning


## Analysis of $\text{Cos}^4$ motion with 1cm peak-to-peak amplitude



- Cylindrical target volume
- Re-scanned different times to same total dose
- Scan times calculated for realistic beam intensities and dead times between spots
- Analysis carried out for different periods of motion

Not always  
improving  
homogeneity with  
number of re-scans!

Marco Schwarz, Trento




Nuclear data for science and  
technology: Medical applications

Future directions and current  
challenges for proton therapy.  
Tony Lomax


# Rescanning

## The 'synchronicity' effect



- Very preliminary results
- A 'real' effect for perfectly regular breathing?
- Could well be less of an issue when breathing is more irregular
- For regular breathing, could be avoided by selecting the re-scanning period to avoid effect or varying period scan-to-scan
- Probably not a big issue in reality?



Marco Schwarz, Trento



# Gating

Reduce magnitude of motion by gating delivery to small window of motion cycle

- + Simple method
- Reliability of gating signal?
- Inter/intra fraction variability of motion?
- Residual motion?








# Gating

- 4D dose calculation applied to cylindrical target in presence of 'real' motion (4D-MRI of volunteers) in liver
- Calculations performed for static, 100, 50 and 30% duty cycles
- Gating signal taken from diaphragm wall motion ('ideal' gating)
- Irregularities in breathing and amplitude over duration of treatment taken into account

- Results for two volunteers


1.  $T_{av} = 4.7s$ ,  $A_{av} = 10.9mm$

2.  $T_{av} = 7.1s$ ,  $A_{av} = 8.3mm$



# Summary.

- Proton therapy is fast moving from the research institute to the hospital
- Due to the adoption of proton therapy in a number of 'flag-ship' institutes in the USA, they will certainly have a higher profile in the next few years.
- Scanning and IMPT will play an ever increasing role in proton therapy, with most manufacturers offering or developing such systems
- However, proton therapy brings challenges in dosimetry, delivery accuracy and organ motion management
- There's lot's of interesting science still to be done....!



## Acknowledgements

Eugen Hug - Head of department and medical chief

Eros Pedroni - Head of R&D and 'brains' of the spot scanning project at PSI

### Medical group

Carmen Ares  
Gudrun Goitein  
Hans Peter Rutz  
Beate Timmermann  
Damien Weber

### Gantry operation

Doelf Coray  
Dani Lempen  
Benno Rohrer  
Hansueli Stauble

### R&D group


Ralph Bearpark  
Terence  
Boehringer  
Christian Bula  
Martin Grossmann  
Christian Hilbes  
Shixiong Lin  
David Meer  
Sairos Safai


### Secretaries

Ruth Eggspuhler  
Frieda Obrist

### Medical Physics group

Tony Lomax  
Francesca Albertini  
Alessandra Bolsi  
Frank Emert  
Jens Heufelder  
Cezarina Negreanu  
Juergen Salk  
Otto Stadelmann  
Jorn Verwey  
Lydia Lederer  
Petra Rhiner  
Heidi Wagner  
Beate Schulz  
Anita Obrist  
Claire Baumeler  
April Siegwolf  
Sandra Hersperger  
Alexander Tourovsky





Thanks for your attention...

